<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Romiplostim: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Romiplostim: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Romiplostim: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="9493" href="/d/html/9493.html" rel="external">see "Romiplostim: Drug information"</a> and <a class="drug drug_patient" data-topicid="12200" href="/d/html/12200.html" rel="external">see "Romiplostim: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F6470287"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Nplate</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52868965"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Nplate</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F8000342"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Colony Stimulating Factor</span>;</li>
<li>
<span class="list-set-name">Thrombopoietic Agent</span></li></ul></div>
<div class="block don drugH1Div" id="F55509726"><span class="drugH1">Dosing: Neonatal</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e29705f5-054a-42c6-9203-df4ea30a513b">Hematopoietic syndrome of acute radiation syndrome</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hematopoietic syndrome of acute radiation syndrome:</b> Term Neonates: SubQ: 10 mcg/kg once; administer dose as soon as possible after suspected or confirmed exposure to radiation levels &gt;2 (gray) Gy; do not delay romiplostim if CBC is not readily available.</p></div>
</div>
</div>
<div class="block dop drugH1Div" id="F52909593"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e29705f5-054a-42c6-9203-df4ea30a513b">Hematopoietic syndrome of acute radiation syndrome</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hematopoietic syndrome of acute radiation syndrome:</b> Infants, Children, and Adolescents: SubQ: 10 mcg/kg once; administer dose as soon as possible after suspected or confirmed exposure to radiation levels &gt;2 (gray) Gy; do not delay romiplostim if CBC is not readily available.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="58acdf8a-6a05-45e7-a020-bd4c6e72f2ed">Immune thrombocytopenia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Immune thrombocytopenia (ITP): Note:</b> Use the lowest dose sufficient to maintain platelet count ≥50,000/mm<sup>3</sup> as necessary to reduce the risk of bleeding. Do not use to normalize platelet counts. Reassess body weight every 12 weeks. Calculate dose using actual body weight.</p>
<p style="text-indent:-2em;margin-left:4em;">Children and Adolescents: SubQ: Initial: 1 mcg/kg/dose once weekly; adjust dose by 1 mcg/kg/week increments to achieve platelet count ≥50,000/mm<sup>3</sup> and to reduce the risk of bleeding; maximum dose: 10 mcg/kg/week.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Dosage adjustment recommendations:</i></p>
<p style="text-indent:-2em;margin-left:8em;">Adjust dose based on platelet count response:</p>
<p style="text-indent:-2em;margin-left:10em;">Platelet count &lt;50,000/mm<sup>3</sup>: Increase weekly dose by 1 mcg/kg.</p>
<p style="text-indent:-2em;margin-left:10em;">Platelet count &gt;200,000/mm<sup>3</sup> to ≤400,000/mm<sup>3</sup> for 2 consecutive weeks: Reduce weekly dose by 1 mcg/kg.</p>
<p style="text-indent:-2em;margin-left:10em;">Platelet count &gt;400,000/mm<sup>3</sup>: Withhold dose; assess platelet count weekly; when platelet count &lt;200,000/mm<sup>3</sup>, resume with the weekly dose reduced by 1 mcg/kg.</p>
<p style="text-indent:-2em;margin-left:10em;">Discontinue if platelet count does not increase to a level sufficient to avoid clinically important bleeding after 4 weeks at the maximum recommended dose of 10 mcg/kg/week.</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F52909594"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block dohp drugH1Div" id="F52909595"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block doa drugH1Div" id="F6470496"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9493" href="/d/html/9493.html" rel="external">see "Romiplostim: Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e29705f5-054a-42c6-9203-df4ea30a513b">Hematopoietic syndrome of acute radiation syndrome</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hematopoietic syndrome of acute radiation syndrome: SubQ:</b> 10 mcg/kg once; begin as soon as possible after suspected or confirmed exposure to radiation levels &gt;2 (gray) Gy; do not delay romiplostim if CBC is not readily available.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="58acdf8a-6a05-45e7-a020-bd4c6e72f2ed">Immune thrombocytopenia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Immune thrombocytopenia:</b>
<b>Note:</b> Use the lowest dose sufficient to maintain platelet count ≥50,000/mm<sup>3</sup> as necessary to reduce the risk of bleeding. Do not use to normalize platelet counts.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>SubQ:</b> Initial: 1 mcg/kg once weekly (based on actual body weight); adjust dose by 1 mcg/kg/week increments to achieve platelet count ≥50,000/mm<sup>3</sup> and to reduce the risk of bleeding; Maximum dose: 10 mcg/kg/week (median dose needed to achieve response in clinical trials: 2 to 3 mcg/kg).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Dosage adjustment recommendations:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Adjust dose based on platelet count response:</p>
<p style="text-indent:-2em;margin-left:8em;">Platelet count &lt;50,000/mm<sup>3</sup>: Increase weekly dose by 1 mcg/kg.</p>
<p style="text-indent:-2em;margin-left:8em;">Platelet count &gt;200,000/mm<sup>3</sup> to ≤400,000/mm<sup>3</sup> for 2 consecutive weeks: Reduce weekly dose by 1 mcg/kg.</p>
<p style="text-indent:-2em;margin-left:8em;">Platelet count &gt;400,000/mm<sup>3</sup>: Withhold dose; assess platelet count weekly; when platelet count &lt;200,000/mm<sup>3</sup>, resume with the weekly dose reduced by 1 mcg/kg.</p>
<p style="text-indent:-2em;margin-left:4em;">Discontinue if platelet count does not increase to a level sufficient to avoid clinically important bleeding after 4 weeks at the maximum recommended dose of 10 mcg/kg/week.</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50990538"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doha drugH1Div" id="F50987855"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block adr drugH1Div" id="F6470355"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Incidences reported are for adult population unless otherwise noted.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin rash (children and adolescents: 15%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (11%), diarrhea (children and adolescents: 20%; adults: ≥5%), upper abdominal pain (children and adolescents: 14%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Acute myelocytic leukemia (4% to 12%), bruise (children and adolescents: 41%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness (17%), headache (35%), insomnia (16%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (26%), limb pain (13%), myalgia (14%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Oropharyngeal pain (children and adolescents: 25%; adults: ≥5%), upper respiratory tract infection (children and adolescents: 31%; adults: ≥5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (children and adolescents: 24%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Peripheral edema (children and adolescents: 7%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Urticaria (children and adolescents: 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Dyspepsia (7%), gastroenteritis (children and adolescents: 5%), nausea (≥5%), vomiting (≥5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Purpuric disease (children and adolescents: 7%), thrombocythemia (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Antibody development (children, adolescents, and adults: 6% to 9%; neutralizing: 3% to 7%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Paresthesia (6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Shoulder pain (8%)</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Otic infection (children and adolescents: 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Bronchitis (≥5%), cough (≥5%), sinusitis (children, adolescents, and adults: ≥5%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%: Hematologic &amp; oncologic: Myelofibrosis (bone marrow reticulin formation/deposition)</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Erythromelalgia, portal vein thrombosis (in patients with chronic liver disease)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis, angioedema, hypersensitivity reaction</p></div>
<div class="block coi drugH1Div" id="F6470298"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">There are no contraindications listed in the manufacturer's US labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Hypersensitivity to romiplostim or any component of the formulation; known history of sensitivity or allergy to any <i>E. coli</i>-derived product.</p></div>
<div class="block war drugH1Div" id="F6470299"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Bone marrow reticulin: May increase the risk for bone marrow reticulin fiber formation; this formation may improve upon discontinuation of therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Concomitant ITP medications: May be used in combination with other therapies for ITP, including corticosteroids, danazol, azathioprine, immune globulin, or Rho(D) immune globulin. Reduce dose of or discontinue ITP medications when platelet count ≥50,000/mm<sup>3</sup>.</p>
<p style="text-indent:-2em;margin-left:4em;">• Error prevention: To prevent overdose or underdose, use caution when calculating dose and appropriate volume for administration (volume may be very small; administer with syringe that allows for 0.01 mL graduations).</p>
<p style="text-indent:-2em;margin-left:4em;">• Hyporesponsiveness: Lack of response or failure to maintain platelet response should trigger investigation into causative factors, including neutralizing antibodies to romiplostim.</p>
<p style="text-indent:-2em;margin-left:4em;">• Malignancy: Progression from existing myelodysplastic syndrome (MDS) to acute myeloid leukemia (AML) has been observed in clinical trials studying romiplostim for severe thrombocytopenia associated with MDS (not an approved indication); a higher percentage of patients receiving romiplostim experienced transformation to AML (compared to placebo). An increase in the percentage of circulating myeloblasts in peripheral blood counts was also noted (both in patients who progressed to AML and in those who did not); blast cells decreased to baseline after discontinuation in some patients.</p>
<p style="text-indent:-2em;margin-left:4em;">• Thromboembolism: Thromboembolism or thrombotic complications with romiplostim therapy may occur from increased platelet counts secondary to drug-induced thrombocytosis, regardless of the underlying disease. Follow dosage adjustment recommendations to minimize the risk for thrombotic or thromboembolic complications. Portal vein thrombosis has been observed in patients with chronic liver disease receiving romiplostim.</p></div>
<div class="block foc drugH1Div" id="F6470502"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Subcutaneous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Nplate: 125 mcg (1 ea); 250 mcg (1 ea); 500 mcg (1 ea)</p></div>
<div class="block geq drugH1Div" id="F6470289"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F16321843"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Nplate Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">125 mcg (per each): $1,502.56</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">250 mcg (per each): $3,005.06</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mcg (per each): $6,010.12</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52868966"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Subcutaneous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Nplate: 250 mcg (1 ea); 500 mcg (1 ea)</p></div>
<div class="block admp drugH1Div" id="F52909598"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Parenteral: SubQ: Administer subcutaneously only. Reconstitute and dilute (if needed [ie, dose &lt; 23 mcg]) prior to administration. Verify calculations, final concentration, and volume drawn up for administration. Concentrations for administration are different based on dose (if dose &lt;23 mcg: Concentration is 125 mcg/mL; if dose ≥23 mcg: Concentration is 500 mcg/mL). Administration volume may be small; only administer using a syringe with 0.01 mL graduations; round dose to the nearest 0.01 mL. Do not pool unused portions from vials; do not administer more than 1 dose from a vial.</p></div>
<div class="block adm drugH1Div" id="F6470498"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">SubQ: Administer subcutaneously only. Administration volume may be small; use appropriate syringe (with graduations to 0.01 mL) for administration. Verify calculations, final concentration, and volume drawn up for administration. Do not pool unused portions from vials; do not administer more than one dose from a vial.</p></div>
<div class="block sts drugH1Div" id="F6470361"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store intact vials at 2°C to 8°C (36°F to 46°F); do not freeze. Protect from light. Store in original carton until use. If needed, unopened vials may be stored in the original carton at room temperature up to a maximum of 25°C (77°F) for a single period of up to 30 days. The new expiration date must be written in the space provided on the carton. Once stored at room temperature, do not place back in the refrigerator. Discard if not used within 30 days. Reconstituted solution (with SWFI) that has not been further diluted may be stored in the original vial at room temperature of 25°C (77°F) or refrigerated at 2°C to 8°C (36°F to 46°F) for up to 24 hours following reconstitution. Reconstituted solution (with SWFI) may be stored in a syringe at room temperature of 25°C (77°F) for a maximum of 4 hours following reconstitution. Protect reconstituted solution from light; do not shake. Solution diluted for infusion with 0.9% sodium chloride (NS) may be stored in a syringe at room temperature of 25°C (77°F) or in the original vial refrigerated at 2°C to 8°C (36°F to 46°F) for no longer than 4 hours prior to administration; protect from light; do not shake. Discard any unused portion.</p></div>
<div class="block meg drugH1Div" id="F7874969"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and at <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2021%2F125268s167lbl.pdf%23page%3D18&amp;token=bjEsZaboosqJlnZXhUcIfrpZnKBUO0MVoPkoe%2Fqkb2uDYKJA3gRa7dqrDus1Xxxkeid7b6XO%2FaSWx3xpqiSA7hbTM%2FGmASsAxe988MwsruGeF6NE3T%2Fw24kJQGTk2RLF&amp;TOPIC_ID=120812" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125268s167lbl.pdf#page=18</a>, must be dispensed with this medication.</p></div>
<div class="block usep drugH1Div" id="F53570293"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of hematopoietic syndrome of acute radiation syndrome (increased survival) (FDA approved all ages); treatment of thrombocytopenia in pediatric patients with immune thrombocytopenic purpura (ITP) for ≥6 months who have had insufficient response to corticosteroids, immune globulin, or splenectomy (FDA approved in ages ≥1 year); treatment of thrombocytopenia in patients with ITP who have had insufficient response to corticosteroids, immune globulin, or splenectomy (FDA approved in adults).</p>
<p style="text-indent:0em;margin-top:2em;">
<b>Note: </b>Romiplostim should be used only when the degree of thrombocytopenia and clinical condition increase the risk for bleeding; romiplostim should not be used in attempt to normalize platelet counts; romiplostim is <b>not</b> indicated for the treatment of thrombocytopenia due to myelodysplastic syndrome or any cause of thrombocytopenia other than chronic ITP.</p></div>
<div class="block mst drugH1Div" id="F9601128"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">RomiPLOStim may be confused with romiDEPsin</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13300015"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F6708337"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Efgartigimod Alfa: May diminish the therapeutic effect of Fc Receptor-Binding Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rozanolixizumab: May diminish the therapeutic effect of Fc Receptor-Binding Agents.<i> Risk C: Monitor therapy</i></p></div>
<div class="block dic drugH1Div" id="F6471447"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Some products may contain sucrose.</p></div>
<div class="block pri drugH1Div" id="F6470295"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Based on data from animal reproduction studies, romiplostim may cause fetal harm if administered to a pregnant patient.</p>
<p style="text-indent:0em;margin-top:2em;">Outcome data following maternal use of romiplostim during pregnancy are available (Bussel 2023; Chua 2020; Howaidi 2022; Michel 2020; Rosa María 2020).</p>
<p style="text-indent:0em;margin-top:2em;">Thrombopoietin (TPO) receptor agonists are not currently a preferred treatment of immune thrombocytopenia during pregnancy; use may be considered in very serious cases when other therapies have failed. If a TPO receptor agonist is needed, use of romiplostim may be considered in the third trimester near delivery (Provan 2019).</p></div>
<div class="block mopp drugH1Div" id="F53570282"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Immune thrombocytopenia (ITP): CBC with differential and platelets at baseline, weekly during dosage adjustment phase, then monthly and weekly for at least 2 weeks following completion of treatment.</p>
<p style="text-indent:0em;margin-top:2em;">Evaluate for neutralizing antibodies in patients with inadequate response (blood samples may be submitted to Amgen for assay [1-800-772-6436]).</p></div>
<div class="block rerp drugH1Div" id="F53569681"><span class="drugH1">Reference Range</span>
<p style="text-indent:0em;display:inline">Immune thrombocytopenia (ITP): Target platelet count of 50,000 to 200,000/mm<sup>3</sup>; platelet life span: 8 to 11 days.</p></div>
<div class="block pha drugH1Div" id="F6470491"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Romiplostim is a thrombopoietin (TPO) peptide mimetic that increases platelet counts in ITP by binding to and activating the human TPO receptor.</p></div>
<div class="block phk drugH1Div" id="F6470483"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: Platelet count increase: SubQ: 4 to 9 days (Wang 2004); Peak platelet count increase: Days 12 to 16 (Wang 2004)</p>
<p style="text-indent:-2em;margin-left:2em;">Duration: Platelet counts return to baseline by day 28 (Wang 2004)</p>
<p style="text-indent:-2em;margin-left:2em;">Absorption: SubQ: Slow (Wang 2004)</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Median: 3.5 days (range: 1 to 34 days)</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, plasma: SubQ: Median: 14 hours (range: 7 to 50 hours)</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F11390219"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Nplate</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Nplate</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Nplate</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Nplate</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Nplate</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Nplate</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Nplate</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Nplate</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Nplate</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Nplate</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Nplate</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Nplate</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Nplate</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Nplate</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Nplate</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Nplate</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Nplate</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Nplate</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Nplate | Romiplate</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Nplate</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Nplate</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Nplate</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Augplat | Romiset | Romy</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Nplate</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Romiplate</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Nplate | Romiplate</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Nplate</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Nplate</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Nplate</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Nplate</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Nplate</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Nplate | Romiplate</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Nplate</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Nplate</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Nplate</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Nplate</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Nplate</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Nplate</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Nplate</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Nplate</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Nplate</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Nplate</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Nplate | Romiplate</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Nplate</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Nplate</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Romiplate</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Nplate</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-21502541">
<a name="21502541"></a>Bussel JB, Buchanan GR, Nugent DJ, et al, “A Randomized, Double-Blind Study of Romiplostim to Determine Its Safety and Efficacy in Children With Immune Thrombocytopenia,” <i>Blood</i>, 2011, 118(1):28-36.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/romiplostim-pediatric-drug-information/abstract-text/21502541/pubmed" id="21502541" target="_blank">21502541</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36156812">
<a name="36156812"></a>Bussel JB, Cooper N, Lawrence T, et al. Romiplostim use in pregnant women with immune thrombocytopenia. <i>Am J Hematol</i>. 2023;98(1):31-40. doi:10.1002/ajh.26743<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/romiplostim-pediatric-drug-information/abstract-text/36156812/pubmed" id="36156812" target="_blank">36156812</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17050891">
<a name="17050891"></a>Bussel JB, Kuter DJ, George JN, et al, “AMG 531, a Thrombopoiesis-Stimulating Protein, for Chronic ITP,” <i>N Engl J Med</i>, 2006, 355(16):1672-81.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/romiplostim-pediatric-drug-information/abstract-text/17050891/pubmed" id="17050891" target="_blank">17050891</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18981291">
<a name="18981291"></a>Bussel JB, Kuter DJ, Pullarkat V, et al, “Safety and Efficacy of Long-Term Treatment With Romiplostim in Thrombocytopenic Patients With Chronic ITP,” <i>Blood</i>, 2009, 113(10):2161-71.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/romiplostim-pediatric-drug-information/abstract-text/18981291/pubmed" id="18981291" target="_blank">18981291</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32284733">
<a name="32284733"></a>Chua SJ, Morton MR, Svigos J, Ross DM, Kane S. Use of romiplostim in pregnancy for refractory idiopathic thrombocytopenic purpura: two case reports with maternal and fetal outcomes and literature review. <i>Obstet Med</i>. 2020;13(1):45-50. doi:10.1177/1753495X18773960<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/romiplostim-pediatric-drug-information/abstract-text/32284733/pubmed" id="32284733" target="_blank">32284733</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34153229">
<a name="34153229"></a>Howaidi J, AlRajhi AM, Howaidi A, AlNajjar FH, Tailor IK. Use of thrombopoietin receptor agonists in pregnancy: a review of the literature. <i>Hematol Oncol Stem Cell Ther</i>. 2022;15(1):1-6. doi:10.1016/j.hemonc.2021.05.004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/romiplostim-pediatric-drug-information/abstract-text/34153229/pubmed" id="34153229" target="_blank">34153229</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18242413">
<a name="18242413"></a>Kuter DJ, Bussel JB, Lyons RM, et al, “Efficacy of Romiplostim in Patients With Chronic Immune Thrombocytopenic Purpura: A Double-Blind Randomised Controlled Trial,” <i>Lancet</i>, 2008, 371(9610):395-403.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/romiplostim-pediatric-drug-information/abstract-text/18242413/pubmed" id="18242413" target="_blank">18242413</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19671919">
<a name="19671919"></a>Kuter DJ, Mufti GJ, Bain BJ, et al, “Evaluation of Bone Marrow Reticulin Formation in Chronic Immune Thrombocytopenia Patients Treated With Romiplostim,” <i>Blood</i>, 2009, 114(18):3748-56.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/romiplostim-pediatric-drug-information/abstract-text/19671919/pubmed" id="19671919" target="_blank">19671919</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21067381">
<a name="21067381"></a>Kuter DJ, Rummel M, Boccia R, et al, “Romiplostim or Standard of Care in Patients With Immune Thrombocytopenia,” <i>N Engl J Med</i>, 2010, 363(20):1889-99.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/romiplostim-pediatric-drug-information/abstract-text/21067381/pubmed" id="21067381" target="_blank">21067381</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32814348">
<a name="32814348"></a>Michel M, Ruggeri M, Gonzalez-Lopez TJ, et al. Use of thrombopoietin receptor agonists for immune thrombocytopenia in pregnancy: results from a multicenter study. <i>Blood</i>. 2020;136(26):3056-3061. doi:10.1182/blood.2020007594<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/romiplostim-pediatric-drug-information/abstract-text/32814348/pubmed" id="32814348" target="_blank">32814348</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Nplate (romiplostim) [prescribing information]. Thousand Oaks, CA: Amgen Inc; February 2022.</div>
</li>
<li>
<div class="reference">
                  Nplate (romiplostim) [product monograph]. Mississauga, Ontario, Canada: Amgen Canada Inc; July 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32430352">
<a name="32430352"></a>Patras A, Figueroa R, Singh AP, Madan I. Romiplostim for management of refractory immune thrombocytopenic purpura in the immediate postpartum period. <i>BMJ Case Rep</i>. 2020;13(5):e234335. doi:10.1136/bcr-2020-234335<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/romiplostim-pediatric-drug-information/abstract-text/32430352/pubmed" id="32430352" target="_blank">32430352</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31770441">
<a name="31770441"></a>Provan D, Arnold DM, Bussel JB, et al. Updated international consensus report on the investigation and management of primary immune thrombocytopenia. <i>Blood Adv</i>. 2019;3(22):3780-3817. doi:10.1182/bloodadvances.2019000812<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/romiplostim-pediatric-drug-information/abstract-text/31770441/pubmed" id="31770441" target="_blank">31770441</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31116059">
<a name="31116059"></a>Rosa María RN, Laura RL, Ángeles PB, Laura LB. Use of romiplostim during pregnancy as a rescue therapy in primary immune thrombocytopenia: literature review and case description. <i>Platelets</i>. 2020;31(3):403-406. doi:10.1080/09537104.2019.1615613<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/romiplostim-pediatric-drug-information/abstract-text/31116059/pubmed" id="31116059" target="_blank">31116059</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15592334">
<a name="15592334"></a>Wang B, Nichol JL, and Sullivan JT, “Pharmacodynamics and Pharmacokinetics of AMG 531, a Novel Thrombopoietin Receptor Ligand,” <i>Clin Pharmacol Ther</i>, 2004, 76(6):628-38.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/romiplostim-pediatric-drug-information/abstract-text/15592334/pubmed" id="15592334" target="_blank">15592334</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 120812 Version 54.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
